Insider Trading Alert - VECO, SPLK, JAZZ, DNDN And LII Traded By Insiders

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Friday, Jan. 10, 2014, 51 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $600.00 to $8,688,240.00.

Highlighted Stocks Traded by Insiders:

Veeco Instruments (VECO) - FREE Research Report

Collingwood Peter who is SVP WW Sales & Field Service at Veeco Instruments sold 6,223 shares at $35.00 on Jan. 10, 2014. Following this transaction, the SVP WW Sales & Field Service owned 5,417 shares meaning that the stake was reduced by 53.46% with the 6,223-share transaction.

Glass David D. who is Evp & Cfo at Veeco Instruments sold 12,948 shares at $35.00 on Jan. 10, 2014. Following this transaction, the Evp & Cfo owned 12,868 shares meaning that the stake was reduced by 50.15% with the 12,948-share transaction.

The shares most recently traded at $35.84, up $0.84, or 2.34% since the insider transaction. Historical insider transactions for Veeco Instruments go as follows:

  • 4-Week # shares sold: 4,019
  • 12-Week # shares sold: 4,019
  • 24-Week # shares sold: 4,019

The average volume for Veeco Instruments has been 672,100 shares per day over the past 30 days. Veeco Instruments has a market cap of $1.4 billion and is part of the technology sector and electronics industry. Shares are up 9.33% year-to-date as of the close of trading on Friday.

Veeco Instruments Inc., together with its subsidiaries, designs, manufactures, and markets process equipment to make light emitting diodes (LEDs) and hard-disk drives worldwide. Currently there are 3 analysts that rate Veeco Instruments a buy, 1 analyst rates it a sell, and 9 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on VECO - FREE

TheStreet Quant Ratings rates Veeco Instruments as a hold. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures and increase in stock price during the past year. However, as a counter to these strengths, we also find weaknesses including feeble growth in the company's earnings per share, deteriorating net income and disappointing return on equity. Get the full Veeco Instruments Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Splunk (SPLK) - FREE Research Report

Neustaetter Thomas M who is Director at Splunk sold 1,500 shares at $75.47 on Jan. 10, 2014. Following this transaction, the Director owned 74,603 shares meaning that the stake was reduced by 1.97% with the 1,500-share transaction.

The shares most recently traded at $74.48, down $0.99, or 1.33% since the insider transaction. Historical insider transactions for Splunk go as follows:

  • 4-Week # shares sold: 12,635
  • 12-Week # shares sold: 43,635
  • 24-Week # shares sold: 304,748

The average volume for Splunk has been 1.2 million shares per day over the past 30 days. Splunk has a market cap of $8.0 billion and is part of the technology sector and computer software & services industry. Shares are up 9.57% year-to-date as of the close of trading on Friday.

Splunk, Inc. provides software solutions that provide real-time operational intelligence. Currently there are 12 analysts that rate Splunk a buy, 1 analyst rates it a sell, and 5 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on SPLK - FREE

TheStreet Quant Ratings rates Splunk as a sell. The company's weaknesses can be seen in multiple areas, such as its deteriorating net income, disappointing return on equity and feeble growth in its earnings per share. Get the full Splunk Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Jazz Pharmaceuticals (JAZZ) - FREE Research Report

Falberg Kathryn E who is EVP and CFO at Jazz Pharmaceuticals sold 2,000 shares at $131.82 on Jan. 10, 2014. Following this transaction, the EVP and CFO owned 126,721 shares meaning that the stake was reduced by 1.55% with the 2,000-share transaction.

The shares most recently traded at $144.69, up $12.87, or 8.89% since the insider transaction. Historical insider transactions for Jazz Pharmaceuticals go as follows:

  • 4-Week # shares sold: 3,000
  • 12-Week # shares sold: 6,000
  • 24-Week # shares sold: 42,208

The average volume for Jazz Pharmaceuticals has been 725,600 shares per day over the past 30 days. Jazz Pharmaceuticals has a market cap of $7.9 billion and is part of the health care sector and drugs industry. Shares are up 9.48% year-to-date as of the close of trading on Friday.

Jazz Pharmaceuticals Public Limited Company, a specialty biopharmaceutical company, engages in the identification, development, and commercialization of pharmaceutical products for various medical needs in the United States, Europe, and other countries. The company has a P/E ratio of 25.3. Currently there are 11 analysts that rate Jazz Pharmaceuticals a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on JAZZ - FREE

TheStreet Quant Ratings rates Jazz Pharmaceuticals as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, expanding profit margins and good cash flow from operations. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full Jazz Pharmaceuticals Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Dendreon (DNDN) - FREE Research Report

Rocco Lindsay who is EVP, Corporate Communications at Dendreon sold 8,207 shares at $2.94 on Jan. 10, 2014. Following this transaction, the EVP, Corporate Communications owned 112,500 shares meaning that the stake was reduced by 6.8% with the 8,207-share transaction.

The shares most recently traded at $3.33, up $0.39, or 11.65% since the insider transaction.

The average volume for Dendreon has been 4.4 million shares per day over the past 30 days. Dendreon has a market cap of $458.3 million and is part of the health care sector and drugs industry. Shares are unchanged year-to-date as of the close of trading on Friday.

Dendreon Corporation, a biotechnology company, engages in the discovery, development, and commercialization of novel therapeutics to enhance cancer treatment options for patients. Currently there is 1 analyst that rates Dendreon a buy, 8 analysts rate it a sell, and 8 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on DNDN - FREE

TheStreet Quant Ratings rates Dendreon as a sell. Among the areas we feel are negative, one of the most important has been a generally disappointing historical performance in the stock itself. Get the full Dendreon Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Lennox International (LII) - FREE Research Report

Bluedorn Todd M who is Chairman and CEO at Lennox International sold 15,649 shares at $86.95 on Jan. 10, 2014. Following this transaction, the Chairman and CEO owned 235,974 shares meaning that the stake was reduced by 6.22% with the 15,649-share transaction.

The shares most recently traded at $87.67, up $0.72, or 0.82% since the insider transaction. Historical insider transactions for Lennox International go as follows:

  • 4-Week # shares sold: 6,974
  • 12-Week # shares sold: 17,575
  • 24-Week # shares sold: 26,118

The average volume for Lennox International has been 382,300 shares per day over the past 30 days. Lennox International has a market cap of $4.3 billion and is part of the industrial goods sector and industrial industry. Shares are up 3.47% year-to-date as of the close of trading on Friday.

Lennox International Inc., through its subsidiaries, designs, manufactures, and markets climate control products for the heating, ventilation, air conditioning, and refrigeration markets. The stock currently has a dividend yield of 1.1%. The company has a P/E ratio of 25.7. Currently there are 2 analysts that rate Lennox International a buy, 2 analysts rate it a sell, and 6 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on LII - FREE

TheStreet Quant Ratings rates Lennox International as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, impressive record of earnings per share growth, compelling growth in net income, revenue growth and notable return on equity. We feel these strengths outweigh the fact that the company shows low profit margins. Get the full Lennox International Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

Data for this article provided by Zacks Investment Research

null

More from Markets

Facebook, Boeing, Shire and Credit Suisse - 5 Things You Must Know

Facebook, Boeing, Shire and Credit Suisse - 5 Things You Must Know

Facebook Prepares for Earnings and 4 Other Stories You Must Know Wednesday

Facebook Prepares for Earnings and 4 Other Stories You Must Know Wednesday

Facebook's Investors Have a Big Day Ahead

Facebook's Investors Have a Big Day Ahead

The Global Stock Market Rout Spreads Across the World

The Global Stock Market Rout Spreads Across the World

Comcast Details $30 Billion Bid for Britain's Sky in Takeover Battle With Fox

Comcast Details $30 Billion Bid for Britain's Sky in Takeover Battle With Fox